Back to top

Image: Bigstock

Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics

Read MoreHide Full Article

Ardelyx (ARDX - Free Report) reported $94.47 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 27.5%. EPS of -$0.15 for the same period compares to -$0.17 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $91.51 million, representing a surprise of +3.24%. The company delivered an EPS surprise of -15.39%, with the consensus EPS estimate being -$0.13.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Ardelyx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Revenues- Product sales, net: $93.37 million versus $89.8 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +37.7% change.
  • Revenues- Product sales, net- IBSRELA: $70.07 million versus $68.02 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +57.8% change.
  • Revenues- Product sales, net- XPHOZAH: $23.3 million versus the five-analyst average estimate of $21.23 million. The reported number represents a year-over-year change of -0.5%.
  • Revenues- Non-cash royalty revenue related to the sale of future royalties: $0.7 million compared to the $1.5 million average estimate based on two analysts. The reported number represents a change of -32.3% year over year.

View all Key Company Metrics for Ardelyx here>>>

Shares of Ardelyx have returned -1.6% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' 7 Best Strong Buy Stocks (New Research Report)

Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.

Click Here, It's Really Free

Published in